FDA Recommends Approval for Ophthalmic Product Enabled By InSite’s DuraSite® Technology
InSite Vision Incorporated has announced that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to recommend approval of Bausch & Lomb’s besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis, a product that utilizes InSite Vision’s DuraSite® patented drug delivery system. DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules in an aqueous matrix, allowing for targeted and sustained administration. DuraSite enables a less frequent dosing schedule, increased patient compliance, and increased efficacy.
- Novagali Pharma launches Cationorm® in France
- FDA nod to Akorn’s Akten™ Ophthalmic Gel 3.5%
- Akorn Announces FDA Approval Of Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%
- VisionCare to give presentations on its implantable telescope technology
